WO1997037996A1 - Cephem compounds and drugs containing the compounds - Google Patents
Cephem compounds and drugs containing the compounds Download PDFInfo
- Publication number
- WO1997037996A1 WO1997037996A1 PCT/JP1997/001161 JP9701161W WO9737996A1 WO 1997037996 A1 WO1997037996 A1 WO 1997037996A1 JP 9701161 W JP9701161 W JP 9701161W WO 9737996 A1 WO9737996 A1 WO 9737996A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- added
- group
- nmr
- mixture
- reduced pressure
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 105
- 239000003814 drug Substances 0.000 title claims description 5
- -1 Cephem compounds Chemical class 0.000 title abstract description 107
- 229940079593 drug Drugs 0.000 title description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 154
- 150000003839 salts Chemical group 0.000 claims abstract description 56
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 27
- 125000003342 alkenyl group Chemical group 0.000 claims abstract description 13
- 125000004429 atom Chemical group 0.000 claims abstract description 7
- 239000001257 hydrogen Substances 0.000 claims abstract description 7
- 125000003367 polycyclic group Polymers 0.000 claims abstract description 6
- 125000002947 alkylene group Chemical group 0.000 claims abstract description 5
- 125000004450 alkenylene group Chemical group 0.000 claims abstract description 4
- 125000002950 monocyclic group Chemical group 0.000 claims abstract description 4
- 125000001841 imino group Chemical group [H]N=* 0.000 claims abstract description 3
- 150000002148 esters Chemical class 0.000 claims description 24
- 125000002252 acyl group Chemical group 0.000 claims description 16
- 125000000623 heterocyclic group Chemical group 0.000 claims description 11
- 150000002430 hydrocarbons Chemical group 0.000 claims description 11
- 229930195733 hydrocarbon Natural products 0.000 claims description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 5
- 239000004215 Carbon black (E152) Substances 0.000 claims description 4
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 2
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 abstract description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract description 6
- 229910052760 oxygen Inorganic materials 0.000 abstract description 4
- 150000001782 cephems Chemical group 0.000 abstract 1
- 150000004677 hydrates Chemical group 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 180
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 138
- 230000002829 reductive effect Effects 0.000 description 136
- 239000000243 solution Substances 0.000 description 133
- 239000000203 mixture Substances 0.000 description 132
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 112
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 105
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 105
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 104
- 238000006243 chemical reaction Methods 0.000 description 85
- 238000001816 cooling Methods 0.000 description 85
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 84
- 238000001914 filtration Methods 0.000 description 76
- 238000003756 stirring Methods 0.000 description 71
- 239000000843 powder Substances 0.000 description 63
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 60
- 235000002639 sodium chloride Nutrition 0.000 description 60
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 57
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 52
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 51
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 48
- 239000007787 solid Substances 0.000 description 42
- 239000013078 crystal Substances 0.000 description 41
- 235000019439 ethyl acetate Nutrition 0.000 description 35
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 33
- 238000004519 manufacturing process Methods 0.000 description 31
- 239000007789 gas Substances 0.000 description 30
- 239000010410 layer Substances 0.000 description 28
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 27
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 27
- 239000005457 ice water Substances 0.000 description 25
- 239000011734 sodium Substances 0.000 description 25
- 229910000104 sodium hydride Inorganic materials 0.000 description 25
- 238000000034 method Methods 0.000 description 23
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 17
- 239000002904 solvent Substances 0.000 description 17
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 15
- 125000000753 cycloalkyl group Chemical group 0.000 description 15
- 239000002253 acid Substances 0.000 description 14
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 14
- 125000004093 cyano group Chemical group *C#N 0.000 description 13
- 239000002198 insoluble material Substances 0.000 description 13
- 239000012452 mother liquor Substances 0.000 description 13
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
- 125000004432 carbon atom Chemical group C* 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 125000003545 alkoxy group Chemical group 0.000 description 11
- 239000000460 chlorine Substances 0.000 description 11
- 239000007864 aqueous solution Substances 0.000 description 10
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 10
- 238000004440 column chromatography Methods 0.000 description 10
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 10
- 229910052757 nitrogen Inorganic materials 0.000 description 10
- 239000012044 organic layer Substances 0.000 description 10
- 238000010992 reflux Methods 0.000 description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- 125000001424 substituent group Chemical group 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 8
- 239000012046 mixed solvent Substances 0.000 description 8
- 238000010898 silica gel chromatography Methods 0.000 description 8
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 7
- 125000003277 amino group Chemical group 0.000 description 7
- 125000003118 aryl group Chemical group 0.000 description 7
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 7
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 7
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 6
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 6
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 6
- 235000008504 concentrate Nutrition 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 5
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 125000003710 aryl alkyl group Chemical group 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 5
- 229910001873 dinitrogen Inorganic materials 0.000 description 5
- 150000002170 ethers Chemical class 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 229910052736 halogen Inorganic materials 0.000 description 5
- 150000002367 halogens Chemical class 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 150000007529 inorganic bases Chemical class 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 150000007530 organic bases Chemical class 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 4
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 4
- 150000008282 halocarbons Chemical class 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 150000002576 ketones Chemical class 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 4
- 150000007522 mineralic acids Chemical class 0.000 description 4
- 150000002825 nitriles Chemical class 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 230000035484 reaction time Effects 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 244000110797 Polygonum persicaria Species 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 3
- 125000004414 alkyl thio group Chemical group 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 125000005604 azodicarboxylate group Chemical group 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 3
- ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000001301 oxygen Chemical group 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 3
- 125000002098 pyridazinyl group Chemical group 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000011593 sulfur Chemical group 0.000 description 3
- 125000004434 sulfur atom Chemical group 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 3
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 239000004258 Ethoxyquin Substances 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- FIWILGQIZHDAQG-UHFFFAOYSA-N NC1=C(C(=O)NCC2=CC=C(C=C2)OCC(F)(F)F)C=C(C(=N1)N)N1N=C(N=C1)C1(CC1)C(F)(F)F Chemical compound NC1=C(C(=O)NCC2=CC=C(C=C2)OCC(F)(F)F)C=C(C(=N1)N)N1N=C(N=C1)C1(CC1)C(F)(F)F FIWILGQIZHDAQG-UHFFFAOYSA-N 0.000 description 2
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 241000775777 Streptococcus agalactiae ATCC 13813 Species 0.000 description 2
- 241001134658 Streptococcus mitis Species 0.000 description 2
- 241000193996 Streptococcus pyogenes Species 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- XMGZWGBXVLJOKE-UHFFFAOYSA-N acetic acid;toluene Chemical compound CC(O)=O.CC1=CC=CC=C1 XMGZWGBXVLJOKE-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 125000003302 alkenyloxy group Chemical group 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 125000006350 alkyl thio alkyl group Chemical group 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 2
- DKPFZGUDAPQIHT-UHFFFAOYSA-N butyl acetate Chemical compound CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 2
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 125000002668 chloroacetyl group Chemical group ClCC(=O)* 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 125000000000 cycloalkoxy group Chemical group 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000002470 cystinyl group Chemical group O=C([*])C(N([H])[H])([H])C([H])([H])SSC([H])([H])C([H])(C(O[H])=O)N([H])[H] 0.000 description 2
- 239000012024 dehydrating agents Substances 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- JQVDAXLFBXTEQA-UHFFFAOYSA-N dibutylamine Chemical compound CCCCNCCCC JQVDAXLFBXTEQA-UHFFFAOYSA-N 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- 238000006266 etherification reaction Methods 0.000 description 2
- DECIPOUIJURFOJ-UHFFFAOYSA-N ethoxyquin Chemical compound N1C(C)(C)C=C(C)C2=CC(OCC)=CC=C21 DECIPOUIJURFOJ-UHFFFAOYSA-N 0.000 description 2
- 229940093500 ethoxyquin Drugs 0.000 description 2
- 235000019285 ethoxyquin Nutrition 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- SPUACDWLOLSOQO-UHFFFAOYSA-M methoxyazanium;chloride Chemical compound [Cl-].CO[NH3+] SPUACDWLOLSOQO-UHFFFAOYSA-M 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000002903 organophosphorus compounds Chemical class 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
- 125000005633 phthalidyl group Chemical group 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 2
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical group C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 2
- 150000003222 pyridines Chemical class 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000005039 triarylmethyl group Chemical group 0.000 description 2
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical group CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 2
- 125000005454 tryptophanyl group Chemical group 0.000 description 2
- 208000019206 urinary tract infection Diseases 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- UNIOAPGQAGSMOR-RTRLPJTCSA-N (3R,4R,5S,6R)-3-(dimethylamino)-6-(hydroxymethyl)oxane-2,4,5-triol Chemical compound CN(C)[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O UNIOAPGQAGSMOR-RTRLPJTCSA-N 0.000 description 1
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- MBIZXFATKUQOOA-UHFFFAOYSA-N 1,3,4-thiadiazole Chemical compound C1=NN=CS1 MBIZXFATKUQOOA-UHFFFAOYSA-N 0.000 description 1
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- 125000005955 1H-indazolyl group Chemical group 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- HVHZEKKZMFRULH-UHFFFAOYSA-N 2,6-ditert-butyl-4-methylpyridine Chemical compound CC1=CC(C(C)(C)C)=NC(C(C)(C)C)=C1 HVHZEKKZMFRULH-UHFFFAOYSA-N 0.000 description 1
- IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 1
- YGZFYDFBHIDIBH-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]icosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCC(CO)N(CCO)CCO YGZFYDFBHIDIBH-UHFFFAOYSA-N 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- AEDQNOLIADXSBB-UHFFFAOYSA-N 3-(dodecylazaniumyl)propanoate Chemical compound CCCCCCCCCCCCNCCC(O)=O AEDQNOLIADXSBB-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000272875 Ardeidae Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010061695 Biliary tract infection Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 101100440696 Caenorhabditis elegans cor-1 gene Proteins 0.000 description 1
- 235000006810 Caesalpinia ciliata Nutrition 0.000 description 1
- 241000059739 Caesalpinia ciliata Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000277306 Esocidae Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 229910010082 LiAlH Inorganic materials 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 241000219470 Mirabilis Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- SVYKKECYCPFKGB-UHFFFAOYSA-N N,N-dimethylcyclohexylamine Chemical compound CN(C)C1CCCCC1 SVYKKECYCPFKGB-UHFFFAOYSA-N 0.000 description 1
- 244000038458 Nepenthes mirabilis Species 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 208000032536 Pseudomonas Infections Diseases 0.000 description 1
- 241000085494 Pseudomonas aeruginosa E2 Species 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- ITLHXEGAYQFOHJ-UHFFFAOYSA-N [diazo(phenyl)methyl]benzene Chemical compound C=1C=CC=CC=1C(=[N+]=[N-])C1=CC=CC=C1 ITLHXEGAYQFOHJ-UHFFFAOYSA-N 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000002814 agar dilution Methods 0.000 description 1
- 125000001980 alanyl group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000000676 alkoxyimino group Chemical group 0.000 description 1
- 125000005153 alkyl sulfamoyl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 1
- JINBYESILADKFW-UHFFFAOYSA-N aminomalonic acid Chemical compound OC(=O)C(N)C(O)=O JINBYESILADKFW-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 150000001449 anionic compounds Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 description 1
- 125000001691 aryl alkyl amino group Chemical group 0.000 description 1
- 125000005099 aryl alkyl carbonyl group Chemical group 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- CHQVQXZFZHACQQ-UHFFFAOYSA-N benzyl(triethyl)azanium hydrobromide Chemical compound Br.CC[N+](CC)(CC)Cc1ccccc1 CHQVQXZFZHACQQ-UHFFFAOYSA-N 0.000 description 1
- CHQVQXZFZHACQQ-UHFFFAOYSA-M benzyl(triethyl)azanium;bromide Chemical compound [Br-].CC[N+](CC)(CC)CC1=CC=CC=C1 CHQVQXZFZHACQQ-UHFFFAOYSA-M 0.000 description 1
- UUZYBYIOAZTMGC-UHFFFAOYSA-M benzyl(trimethyl)azanium;bromide Chemical compound [Br-].C[N+](C)(C)CC1=CC=CC=C1 UUZYBYIOAZTMGC-UHFFFAOYSA-M 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 230000006315 carbonylation Effects 0.000 description 1
- 238000005810 carbonylation reaction Methods 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- QHTOIDKCEPKVCM-ZCFIWIBFSA-N cepham Chemical compound S1CCCN2C(=O)C[C@H]21 QHTOIDKCEPKVCM-ZCFIWIBFSA-N 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- LADPCMZCENPFGV-UHFFFAOYSA-N chloromethoxymethylbenzene Chemical compound ClCOCC1=CC=CC=C1 LADPCMZCENPFGV-UHFFFAOYSA-N 0.000 description 1
- 208000003167 cholangitis Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- ONCCWDRMOZMNSM-FBCQKBJTSA-N compound Z Chemical compound N1=C2C(=O)NC(N)=NC2=NC=C1C(=O)[C@H]1OP(O)(=O)OC[C@H]1O ONCCWDRMOZMNSM-FBCQKBJTSA-N 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 125000006310 cycloalkyl amino group Chemical group 0.000 description 1
- 125000006637 cyclobutyl carbonyl group Chemical group 0.000 description 1
- 125000006640 cycloheptyl carbonyl group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000006639 cyclohexyl carbonyl group Chemical group 0.000 description 1
- 125000004956 cyclohexylene group Chemical group 0.000 description 1
- 125000006638 cyclopentyl carbonyl group Chemical group 0.000 description 1
- 125000006255 cyclopropyl carbonyl group Chemical group [H]C1([H])C([H])([H])C1([H])C(*)=O 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- JEQRBTDTEKWZBW-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1=C(O)OC(C)=CC1=O JEQRBTDTEKWZBW-UHFFFAOYSA-N 0.000 description 1
- 229940061632 dehydroacetic acid Drugs 0.000 description 1
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- WBKFWQBXFREOFH-UHFFFAOYSA-N dichloromethane;ethyl acetate Chemical compound ClCCl.CCOC(C)=O WBKFWQBXFREOFH-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Chemical compound CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- HPYNZHMRTTWQTB-UHFFFAOYSA-N dimethylpyridine Natural products CC1=CC=CN=C1C HPYNZHMRTTWQTB-UHFFFAOYSA-N 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- OYZFAJDTEBIFQW-UHFFFAOYSA-N hexan-1-amine;zinc Chemical compound [Zn].CCCCCCN OYZFAJDTEBIFQW-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 125000005946 imidazo[1,2-a]pyridyl group Chemical group 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910001412 inorganic anion Inorganic materials 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 125000001998 leucyl group Chemical group 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- 125000001288 lysyl group Chemical group 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 125000003099 maleoyl group Chemical group C(\C=C/C(=O)*)(=O)* 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- WVJKHCGMRZGIJH-UHFFFAOYSA-N methanetriamine Chemical compound NC(N)N WVJKHCGMRZGIJH-UHFFFAOYSA-N 0.000 description 1
- 125000002073 methionyl group Chemical group 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- ACYBVNYNIZTUIL-UHFFFAOYSA-N n'-benzylethane-1,2-diamine Chemical compound NCCNCC1=CC=CC=C1 ACYBVNYNIZTUIL-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000005029 naphthylthio group Chemical group C1(=CC=CC2=CC=CC=C12)S* 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- RJMUSRYZPJIFPJ-UHFFFAOYSA-N niclosamide Chemical compound OC1=CC=C(Cl)C=C1C(=O)NC1=CC=C([N+]([O-])=O)C=C1Cl RJMUSRYZPJIFPJ-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000000018 nitroso group Chemical group N(=O)* 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 229960000649 oxyphenbutazone Drugs 0.000 description 1
- CNDQSXOVEQXJOE-UHFFFAOYSA-N oxyphenbutazone hydrate Chemical compound O.O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 CNDQSXOVEQXJOE-UHFFFAOYSA-N 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 150000002960 penicillins Chemical group 0.000 description 1
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 125000005954 phenoxathiinyl group Chemical group 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 1
- 229940116357 potassium thiocyanate Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229960003857 proglumide Drugs 0.000 description 1
- 125000006410 propenylene group Chemical group 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 125000002072 seryl group Chemical group 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000001433 sodium tartrate Substances 0.000 description 1
- 229960002167 sodium tartrate Drugs 0.000 description 1
- 235000011004 sodium tartrates Nutrition 0.000 description 1
- VGTPCRGMBIAPIM-UHFFFAOYSA-M sodium thiocyanate Chemical compound [Na+].[S-]C#N VGTPCRGMBIAPIM-UHFFFAOYSA-M 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- RUPAXCPQAAOIPB-UHFFFAOYSA-N tert-butyl formate Chemical group CC(C)(C)OC=O RUPAXCPQAAOIPB-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000004627 thianthrenyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3SC12)* 0.000 description 1
- CBDKQYKMCICBOF-UHFFFAOYSA-N thiazoline Chemical compound C1CN=CS1 CBDKQYKMCICBOF-UHFFFAOYSA-N 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000001166 thiolanyl group Chemical group 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 125000001239 threonyl group Chemical group 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 239000012929 tonicity agent Substances 0.000 description 1
- CFOAUYCPAUGDFF-UHFFFAOYSA-N tosmic Chemical compound CC1=CC=C(S(=O)(=O)C[N+]#[C-])C=C1 CFOAUYCPAUGDFF-UHFFFAOYSA-N 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 239000006150 trypticase soy agar Substances 0.000 description 1
- 125000002233 tyrosyl group Chemical group 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 229940100050 virazole Drugs 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/14—Compounds having a nitrogen atom directly attached in position 7
- C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
- C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
- C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
- C07D501/38—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
Definitions
- the present invention relates to a novel cefyumu compound, a method for producing the compound, an intermediate, and a medicament containing the compound.
- JP-A-60-237090 As a compound having a pyridiniomethyl group which may be substituted at the 3-position of the septum ring, JP-A-60-237090 (WO 8505106, EP 160969 A2). Patent applications such as 64740 B1, USP 5071979) and Japanese Patent Publication No. 2-444676 (EP 159011 B1, USP 4833242), etc., in which a pyridinium ring is substituted with a heterocyclic group having one CONHCN or a similar substituent. Compounds have not yet been reported.
- cefm compounds are commercially available, but it is necessary to develop and characterize compounds with better antibacterial activity in order to respond to the emergence of multidrug-resistant bacteria and the diversification of treatment forms.
- the present inventors have conducted repeated studies with the aim of developing a novel cefum compound having excellent properties.As a result, they have a pyridiniomethyl group at the 3-position of the cefyumu ring, and have one CONHCN Or, a cefnium compound substituted by a heterocyclic ring having a similar substituent has excellent pharmacokinetic properties. I found to do.
- Het is a monocyclic or polycyclic heterocyclic ring containing one or more same or different atoms selected from N, 0 and S;
- R 1 is hydrogen, an optionally substituted lower alkyl
- Or represents an optionally substituted lower alkenyl
- A represents an optionally substituted lower alkylene, an optionally substituted lower alkenylene or a single bond
- B represents an optionally substituted imino or a single bond Represents a single bond or
- the compounds of the invention preferably have the formula I:
- Het in the above formula I or II is preferably a 5- or 6-membered trivalent heterocyclic group containing 1 to 4 identical or different atoms selected from N, 0 and S, and formula IV : Is more preferred.
- A is a single bond or a vinyl group
- B is a single bond
- D is a single bond
- X is CH or N; Y is an optionally protected amino; Z is a hydrogen or an optionally substituted hydrocarbon group
- Het is a 5- or 6-membered heterocyclic ring containing 1 to 4 identical or different atoms selected from N, 0 and S;
- A is a single bond or a vinyl group;
- Bond a compound in which D is a single bond, or an ester or a salt or hydrate thereof.
- the septum compound refers to a group of compounds named based on “cepham” described in The Journal of the American Chemical Society, 84, 3400 (1962). A compound having a double bond at the position.
- the compound of the present invention is a compound of the general formula I or a pharmaceutically acceptable ester or a salt or hydrate thereof (an ester of the compound I, a salt of the compound I and a salt of the ester of the compound I or a hydrate thereof) ).
- (-) at the 4-CO at the 4-position is a carboxylate anion, which forms an inner salt when paired with the pyridinium cation on the 3-position substituent.
- the pyridinium cation forms a salt with an anion or a counter ion present on the side chain, and any form is within the scope of the present invention. is there. Further, the 1-position S of the septum compound may be oxidized.
- monocyclic or polycyclic heterocyclic ring means both aromatic and non-aromatic monocyclic or polycyclic heterocyclic ring, and is bonded to three adjacent groups. are doing.
- aromatic heterocycles are preferably 5- to 6-membered, which are furan, thiophene, tetrazole, pyrrol, pyrazole, imidazole, oxazole, thiazole, pyridine. Oxazine or triazine.
- the non-aromatic heterocyclic ring is preferably a 5- to 7-membered ring group, such as pyrrolidine, thiazolidine, oxazolidin, imidazolidin, thiazoline, oxazoline, imidazoline, piperidine, piperazine, morpholine, thiomorpholine, oxaziazoline. And dioxane. Among them, those containing one or two N or S atoms Rings are preferred, and pyrrole is most preferred.
- a polycyclic heterocyclic ring preferably, a benzene ring, a pyridine ring, a pyrazine ring, a pyridazine ring, a pyrimidine ring is used as the above monocyclic aromatic heterocyclic ring such as benzothiophene, indole, benzothiazole, benzofuran, and benzimidazole. And the like are exemplified by condensed rings.
- Het is attached to position 4 of the pyridinium ring.
- “Lower alkyl” in the definition of R 1 means a straight-chain or branched alkyl group, and includes methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, Examples include isopentyl, neopentyl, tert-pentyl, 1-ethylpropyl, hexyl, isohexyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, 2-ethylbutyl and the like.
- d- 4 alkyl such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl and the like are preferred.
- Such lower alkyl group for example, a lower alkenyl group - hexyl (eg, vinyl, butenyl, C 2 etc. propenyl etc.
- a cycloalkyl group e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexylene, consequent C of heptyl and the like to the mouth 3 - 7 cycloalkyl group
- Ariru group e.g., full X alkenyl, C 6 of naphthyl - like 10 Ariru group, said Ariru group further hydroxyl, methyl, etc.
- Echiru CI- 4 May be substituted with a d- 4 alkoxy group such as an alkyl group, methoxy, ethoxyquin, etc.), an aromatic heterocyclic group (eg, furyl, phenyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl) , 1,2,3-oxadiazolyl, 1,2,4 monooxadiazolyl, 1,3,4-oxadiazolyl, furaza Le, 1, 2, 3-thiadiazolyl, 1, 2, 4-thiadiazolyl, 1, 3, 4-thiadiazole Lil, 1, 2, 3 Toriazoriru, 1, 2, 4 Toriazoriru, tetrazolyl, 5- to 6-membered aromatic heterocyclic groups containing 1 to 4 heteroatoms such as nitrogen, oxygen, and sulfur such as pyridyl, pyridazinyl, pyrimidiny
- lower alkenyl C 2 linear or branched - 6 alkenyl group and meaning taste, Ariru, propenyl, butenyl, pentenyl and the like are exemplified, Ariru are preferred. These may be substituted with the same substituents as those described above for lower alkyl.
- lower alkylene in the definition of A means a group derived from the above lower alkyl, examples of which include methylene, ethylene, butylene, propylene, and pentylene, with methylene and ethylene being preferred. These may be substituted with the same substituents as those described above for lower alkyl.
- “Lower alkenylene” means a group derived from the above lower alkenyl, and examples thereof include vinylene, butenylene, and propenylene, and vinylene is preferred. These may be substituted with the same substituents as those described above for the lower alkyl.
- the “acyl group” represented by Acyl includes an acyl group substituted for the amino group at position 6 of a conventionally known penicillin derivative and an amino group substituted for the amino group at position 7 of a cefyumu compound. And so on.
- Examples of such an acyl group include an acyl group derived from an organic carboxylic acid, such as a formyl group, an alkylcarbonyl group (an alkanoyl group), and preferably ((:!- ⁇ alkyl-carbonyl group (eg, acetyl, propionyl) , butyryl, iso-butyryl, valeryl, isovaleryl, Kisanoiru like pivaloyl to,), C 3 - 5 Arukenoiru group (eg, Akuriroiru, black Tonoiru, maleoyl, etc.), C 3 _ 1 0 cycloalkyl one carbonyl group (e.g., cyclopropyl Carbonyl, cyclobut
- an aralkylcarbonyl group preferably a (C 7 -C 19 ) aralkyl monocarbonyl group (eg, phenylacetyl, phenylpropionyl, ⁇ ,, 1-triphenylacetyl, 2-phenyl) Netylcarbonyl, 1- or 2-naphthylmethylcarbonyl, benzhydrylcarbonyl, etc., 5- to 6-membered aromatic heterocyclic carbonyl group (eg, 2- or 3-tenol, 2- or
- glycyl alanyl, nokril, leucyl, isoleucyl, seryl, threonyl, cystinyl, cystinyl, methionyl, asparagyl, glutamyl, lysyl, arginyl, fuunildaricyl, phenylalalanyl, tyrosyl, histidyl, tryptophanyl, tryptophanyl Carbonyl, 3-aminopropylcarbonyl and other amino d- 6 alkyl-carbonyl groups, etc., monoalkylaminoalkylcarbonyl groups (eg, monoamino such as methylaminomethylcarbonyl, 2-ethylaminoaminocarbonyl, etc.)
- monoalkylaminoalkylcarbonyl groups eg, monoamino such as methylaminomethylcarbonyl, 2-ethylaminoaminocarbonyl, etc.
- dialkyl ⁇ amino alkylcarbonyl group e.g., dimethyl ⁇ amino methyl carbonyl, di C i-6 Arukiruamino C such Jechiru aminomethyl carbonyl] - 6 alkyl one local Boniru And the like.
- Ashiru groups Amino, nitro, halogen (e.g., fluorine, chlorine, bromine, etc.), human Dorokishiru, Okiso force Rubamoiru, (C! -C 4) alkyl (e.g., methyl, Echiru, propyl, isopropyl, butyl, etc.) , (C CJ ⁇ Rukokin (eg, main butoxy, Etokin, Purobokishi, Butokin etc.), which may be ester le carboxyl (e.g., main butoxycarbonyl, C etc. ethoxy force carbonyl, - 6 alkoxycarbonyl and the like) , Which may be substituted with carboxyl, halogen, or the like.
- halogen e.g., fluorine, chlorine, bromine, etc.
- C! -C 4 alkyl e.g., methyl, Echiru, propyl, isopropyl, butyl, etc.
- an aromatic heterocycle containing 1 to 4 heteroatoms such as an oxygen atom, a sulfur atom (which may be mono- or di-oxidized).
- heteroatoms such as an oxygen atom, a sulfur atom (which may be mono- or di-oxidized).
- examples include pyrrole, imidazole, virazole, pyrimidine, virazine, pyridazine, indole, isothiazole, oxazole, isoxazole, and triazole.
- Acyl a group represented by the above formula ⁇ (X is CH or ;; ⁇ is a protected or unsubstituted amino; ⁇ is a hydrogen or an optionally substituted hydrocarbon group) is preferable.
- protecting group for the amino group in the definition of ⁇ for example, those used in the field of ⁇ -lactam and peptide can be appropriately adopted, and among them, formyl, chloroacetyl, tertiary butynecarbonyl, benzylo Xycarbonyl, ⁇ -methoxybenzyloxycarbonyl, ⁇ -methoxybenzyloxycarbonyl, 2-trimethylsilylethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, trityl and the like are preferred.
- hydrocarbon group in the definition of ⁇ for example, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, aralkyl, di- or triarylmethyl group, aryl group and the like are used.
- a lower alkyl group is a linear or branched alkyl group having preferably 1 to 6 carbon atoms and the like, and is methyl, ethyl, ⁇ -propyl, isopropyl, ⁇ -butyl, isobutyl, sec-butyl. Tert-butyl, n-pentyl, n-hexyl and the like.
- the lower alkenyl group is a linear or branched alkenyl group preferably having 2 to 6 carbon atoms, and examples thereof include aryl, propenyl, butenyl, pentenyl and the like.
- the lower alkynyl group is a linear or branched alkynyl group preferably having 2 to 6 carbon atoms, and examples thereof include propynyl, butynyl, pentynyl and the like.
- the cycloalkyl group is preferably a cycloalkyl group having 3 to 6 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like.
- the aralkyl group is preferably an aralkyl group having 7 to 10 carbon atoms, such as a benzyl group.
- the di- or triaryl-methyl group is preferably a di- or tri- (C 6 , 0-aryl) -methyl group and the like; benzhydryl, di (p-tolyl) methyl, trityl, tri (p) Monotolyl) methyl and the like.
- the aryl group is an aryl group having 6 to 10 carbon atoms, such as a phenyl group.
- the hydrocarbon group represented by Z is, for example, a carboxyl group: an alkoxy-carbonyl group having 1 to 6 carbon atoms such as methoxycarbonyl and ethoxycarbonyl; a carbamoyl group; an alkylthio group having 1 to 6 carbon atoms such as methylthio and ethylthio.
- a group; a sulfamoyl group; an amino group; a hydroxyl group; a cyano group; a carbamoyloxy group; and 1 to 3 substituents such as halogen such as fluorine and chlorine may be substituted.
- a hydrogen atom, C 1 -C 3 lower alkyl or halogen or one or two substituted lower alkyl group with a carboxyl group are preferable.
- the ester derivative of the compound of the present invention or an intermediate means an ester that can be formed by esterifying a carboxyl group contained in a molecule, and includes an ester that can be used as an intermediate for synthesis and a nontoxic substitute that can be hydrolyzed in vivo. It is a pleased ester.
- Examples of the metabolic ester residue include acetoxmethyl group, 1-acetoxicetyl group, 1-acetoxypropyl group, bivaloyloquinmethyl group, 1-isopropyloxycarbonyloxyxetyl group, 1-six mouth Hexyloxycarbonyloxetyl group, phthalidyl group, (2-oxo- Chill-1,3-dioxol-4-yl) Methyl group, etc.
- ester residue may be, for example, a compound of formula VIII:
- R 7 is a hydrogen atom, an alkyl group, a cycloalkyl group or a cycloalkylalkyl group
- R 8 is a hydrogen atom, an alkyl group, a cycloalkyl group, an alkoxy group, a cycloalkyloxy group, a cycloalkylalkyl group, Alkenyl group or phenyl group
- the alkyl group and the alkyl group in the cycloalkylalkyl, the alkoxyalkyl group and the alkylthioalkyl group include a linear or branched alkyl group having 1 to 6 carbon atoms (eg, methyl, ethyl, propyl, isopropyl,
- Examples of the cycloalkyl group and the cycloalkyl group of the cycloalkyloxy group or the cycloalkylalkyl group such as butyl, 2,2-dimethylpropyl, etc. include, for example, a cycloalkyl group having 3 to 7 carbon atoms (eg, cyclopropyl).
- alkoxy group and the alkoxy group in the alkoxyalkyl group include a straight chain having 1 to 10 carbon atoms. Or a branched alkoxy group (eg, methoxy, ethoxyquin, propoxy, isopropoxy, butoxy, hexyloxy, decyloxy, etc.).
- alkenyloxy group include a linear or branched alkenyloxy group having 2 to 7 carbon atoms (eg, aryloxy, etc.).
- the salt of the compound of the present invention is preferably a pharmaceutically acceptable salt, a salt with an inorganic base, a salt with an organic base, a salt with an inorganic acid, a salt with an organic acid, a salt with a basic or acidic amino acid,
- the salt include an intramolecular salt.
- salts with inorganic bases include alkali metal salts such as sodium salt and potassium salt: alkaline earth metal salts such as calcium salt and magnesium salt; and aluminum salts, ammonium salts and the like. Is done.
- Preferred examples of the salt with an organic base include trimethylamine, triethylamine, pyridine, picolin, ethanolamine, diethanolamine, triethanolamine, dicyclohexylamine, ⁇ , ⁇ '-diamine. Examples thereof include salts with benzylethylenediamine, procarine, 2-phenylethylbenzylamine, trishydroxymethylaminoaminomethane, polyhydroxyalkylamine, and dimethylglucosamine.
- Preferred examples of the salt with an inorganic acid include salts with hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, and the like.
- Preferred examples of salts with organic acids include formic acid, acetic acid, trifluoroacetic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, conodic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, Examples thereof include salts with ⁇ -toluenesulfonic acid and the like.
- Preferred examples of the salt with a basic amino acid include salts with arginine, lysine, orditin, histidine, and the like.
- Preferred examples of the salt with an acidic amino acid include aspartic acid, glutamic acid, and the like. Are exemplified.
- salts with bases are the carboxy groups at the 4-position of the cephalic ring of the compound of the present invention. It means a salt that can be formed when an acid group such as a carboxyl group, a sulfo group, or a hydroxy group is present on a side chain or a sil group.
- Salts with acids i.e., salts with inorganic acids, salts with organic acids, salts with acidic amino acids
- a salt that can be formed when a basic group such as a group, an aralkylamino group, or a nitrogen-containing heterocyclic group is present.
- an organic or organic moiety is formed at the portion forming the inner salt of the compound of the present invention, that is, the carboxylate portion (COO—) at the 4-position and the pyridinium cation portion on the 3-position side chain.
- Salts having 1 mole of an inorganic acid and having a counter ion such as chloride ion, promide ion, sulfate ion, p-toluene sulfonate ion, methane sulfonate ion, trifluoroacetate ion are also included. .
- the hydrate in the present invention means, for example, monohydrate and dihydrate. These can be obtained by appropriately controlling the drying method.
- the compound of the present invention can be appropriately produced using a known method in the field of lactam. The typical production methods are shown below.
- R 4 represents a carboxy protecting group
- R 5 represents a hydroxyl group, an acyloxy group, a rubamoyloxy group, a substituting rubamoyloxy group or a halogen atom
- a formula VI ⁇ ⁇ - ⁇ - ⁇ -CO-D-NHCN
- compound V or a salt thereof (hereinafter sometimes abbreviated as compound V) is reacted with a pyridine derivative VI or a salt thereof (hereinafter sometimes abbreviated as compound VI), and the compound is subjected to a nucleophilic substitution reaction.
- a pyridine derivative VI or a salt thereof hereinafter sometimes abbreviated as compound VI
- Compound V can be easily produced by a known method (for example, the method described in JP-A-62-31684, JP-A-62-149682, etc.) or a method analogous thereto. it can.
- compound VI is produced, for example, by a method described in Examples described later.
- the nucleophilic substitution reaction of compound V with compound VI is usually performed in a solvent.
- Solvents used in this reaction include ethers (dioxane, tetrahydrofuran, getyl ether, etc.), esters (ethyl formate, ethyl acetate, n-butyl acetate, etc.), and halogenated hydrocarbons (dichloromethane, chloroform).
- compound VI is a liquid, a large excess of compound VI over compound V (eg (For example, 10 to 200 times the molar amount).
- the above solvent may not be used, or the above solvent and compound VI may be used as a mixed solvent.
- a more preferred solvent is water or a mixed solvent of water and an organic solvent miscible with water. Tons, methyl ethyl ketone, acetonitrile, etc.
- the amount of compound VI to be used is generally about 1-5 mol, preferably about 1-3 mol, per 1 mol of compound V.
- the reaction is carried out in a temperature range of about 10-100, preferably about 30-80C.
- the reaction time depends on the type of compound V and compound VI, the type of solvent, the reaction temperature and the like, and is usually from tens of minutes to several hours, preferably about 1 to 5 hours.
- the reaction is advantageously carried out at pH 2-8, preferably near neutral, ie pH 5-8.
- This reaction usually proceeds more easily in the presence of 2 to 30 equivalents of iodide or thiocyanate.
- iodide or thiocyanate examples include sodium iodide, potassium iodide, sodium thiocyanate, potassium thiocyanate and the like.
- the reaction is carried out by adding a quaternary ammonium salt having a surface-active action such as, for example, trimethylbenzylammonium bromide, triethylbenzylammonium bromide, or triethylbenzylammonium hydrobromide.
- an organic phosphorus compound may be used according to a method described in, for example, JP-A-58-43979 (USP 464,365, US Pat. Performed in the presence of compound.
- the solvent used in the reaction is preferably the above-mentioned ethers, esters, halogenated hydrocarbons, hydrocarbons, amides, ketones, nitriles, sulfols, etc. Foxides or the like are used alone or as a mixed solvent.
- good effects can be obtained by using, for example, dichloromethane, acetonitrile, dimethylformamide, dimethylsulfoxide, a mixed solvent of dimethylformamide and acetonitrile, a mixed solvent of dichloromethane and acetonitrile, and the like.
- Compound VI or a salt thereof and an organic phosphorus compound are used in an amount of about 1 to 5 mol, about 1 to 10 mol, more preferably about 1 to 3 mol, and about 1 to 6 mol, respectively, per 1 mol of compound V. It is.
- the reaction is carried out in a temperature range of about -80 to 50 ° C, preferably about -40 to 40 ° C.
- the reaction time is usually about 30 minutes to 48 hours, preferably about 1 to 24 hours.
- An organic base may be added to the reaction system. Examples of such organic bases include amines such as triethylamine, tri (n-butyl) amine, di (n-butyl) amine, cisisobutylamine, and zinc hexylamine.
- the amount of the base added is preferably about 1 to 5 mol per 1 mol of the compound V.
- R 5 is a halogen atom (preferably iodine) in compound V
- preferred solvents are the above-mentioned ethers, esters, halogenated hydrocarbons, hydrocarbons, amides, ketones, nitriles , Alcohols, water, sulfoxides and the like.
- the amount of compound VI to be used is generally about 1-5 mol, preferably about 1-3 mol, per 1 mol of compound V.
- the reaction is about 0-80. C, preferably at a temperature in the range of about 20 to 60 ° C.
- the reaction time is generally about 30 minutes to 15 hours, preferably about 1 to 5 hours.
- the reaction can be carried out in the presence of a dehalogenating agent to promote the reaction.
- Such dehydrohalogenating agents include inorganic bases (sodium carbonate, potassium carbonate, calcium carbonate, sodium bicarbonate, etc.), tertiary amines (triethylamine, tri (n-propyl) amine, Tri (n-butyl) amine, diisopropylethylamine, cyclohexyldimethylamine, pyridine, lutidine, etc.), Deoxidizing agents such as alkylene oxides (propylene oxide, epichlorohydrin, etc.) can be used, but compound VI itself may be used as a dehydrohalogenating agent. In this case, compound VI is used in an amount of 2 mol or more per 1 mol of compound V.
- inorganic bases sodium carbonate, potassium carbonate, calcium carbonate, sodium bicarbonate, etc.
- tertiary amines triethylamine, tri (n-propyl) amine, Tri (n-butyl) amine, diisopropyleth
- a compound represented by the general formula ZOH (Z is as defined above) or a reactive derivative thereof is reacted with a hydroxyimino derivative represented by the formula (I) or an ester or salt thereof to produce the compound by an etherification reaction.
- the reactive derivative of Z OH may be any as long as it can replace the hydrogen atom of the hydroxyimino compound VII with Z.
- the general formula ZR 6 (where R 6 is, for example, a halogen atom, a monosubstituted sulfonyloxy group, etc. And the like) are used.
- Monosubstituted Suruhoniruokishi group as for example methanesulfonyl Okishi, ethanesulfonyl O Kin, benzenesulfonyl O carboxymethyl, p- toluene sulfonyl O carboxymethyl such as d - 6 alkylsulfonyl O carboxymethyl group, C 6 - 10 7 Li one Rusuruhoniru And the like.
- Hydroxyminino compound VII can be synthesized by the methods described herein or by methods known in the art.
- the compound ZOH and its reactive derivative can be prepared by known methods (for example, the methods described in JP-A-60-231684, JP-A-62-149682, etc.) or It can be easily synthesized by a method corresponding thereto.
- the compound I is synthesized by reacting the hydroxyimino compound VII with the compound ZOH using an appropriate dehydrating agent.
- the dehydrating agent used for this purpose include phosphorus oxychloride, thionyl chloride, dialkyl azodicarboxylate (usually used in the presence of phosphine), and N, N'-hexylcarboximidine. And the like.
- getyl azodicarboxylate in the presence of triphenylphosphine is usually carried out in an anhydrous solvent, and ethers, hydrocarbons and the like exemplified above are used.
- Hydroxyimino compound VII Compound Z O per mole
- H, ethyl azodicarboxylate, and triphenylphosphine are all about 1 to
- the reaction between ZR 6 and the heat Dorokishiimino compound V II is a conventional etherification reaction carried out in a solvent.
- a solvent the above-mentioned ethers, esters, halogenated hydrocarbons, hydrocarbons, amides, ketones, nitriles, alcohols, water and the like or a mixed solvent can be used.
- Preferred is a mixed solvent of water and a water-miscible solvent (eg, aqueous methanol, aqueous ethanol, aqueous acetone, aqueous dimethyl sulfoxide, etc.). This reaction can be allowed to proceed smoothly in the presence of an appropriate base.
- Such bases include, for example, alkali metal salts such as sodium carbonate, sodium hydrogen carbonate, and lithium carbonate, and inorganic bases such as alkali metal hydroxide such as sodium hydroxide and lithium hydroxide.
- This reaction may be carried out in a buffer solution (pH buffer, etc.) of pH 7.5 to 8.5.
- Starting compound V II Number of moles of compound ZR 6 and base per mole of compound Is about 1 to 5 and about 1 to 10, respectively, preferably about 1 to 3 and about 1 to 5 respectively.
- the reaction temperature is in the range of about ⁇ 30 to 100 ° C., preferably about 0 to 80 ° C.
- the reaction time is about 10 minutes to 15 hours, preferably about 30 minutes to 5 hours.
- amino, hydroxy, carboxyl, and other functional groups may be appropriately protected with a protecting group.
- Protective group removal method For example, monohalogenoacetyl group (chloroacetyl, bromoacetyl, etc.) is treated with thiourea, and alkoxycarbonyl group (methoxycarbonyl, ethoxyquincarbonyl, tert-butoxycarbonyl, etc.) is treated with acid (eg, hydrochloric acid, etc.).
- monohalogenoacetyl group chloroacetyl, bromoacetyl, etc.
- alkoxycarbonyl group methoxycarbonyl, ethoxyquincarbonyl, tert-butoxycarbonyl, etc.
- acid eg, hydrochloric acid, etc.
- aralkyloxycarbonyl groups (benzyloxycarbonyl, p-methylbenzyloxycarbonyl, p-nitrobenzoyloxycarbonyl, etc.) can be reduced by catalytic reduction to 2,2,2-trichloroethoxyquinolcarbonyl with zinc and acid ( 2-methylsulfonylethyl ester is converted to alkali, and aralkyl esters (benzyl ester, p-methoxybenzyl ester, p-nitrobenzyl ester, etc.) are converted to acids (for example, formic acid, trifluoroacetic acid, etc.).
- the compound of the present invention or a synthetic intermediate thereof obtained by the above-mentioned or other production methods can be isolated and purified by a known processing means such as an extraction method, column chromatography, precipitation method, and recrystallization method. .
- the isolated compound is converted into a desired physiologically acceptable salt by a known method. Can also be.
- the compound of the present invention is useful as a pharmaceutical, especially a valuable antibiotic because it has a broad spectrum antibacterial activity, has a long blood half-life, and has excellent pharmacokinetic properties.
- Direct or indirect use for the prevention and treatment of various diseases caused by pathogenic bacteria in eg, mice, rats, egrets, dogs, cats, cattle, pigs, etc.
- eg, respiratory and urinary tract infections Can be done.
- the features of the antibacterial spectrum are as follows.
- MRSA methicillin-resistant staphylococci
- Aminoglycoside antibiotics such as amikacin and gentamicin have been used for microorganisms of the genus Pseudomonas in particular. It has significant advantages because it is much less toxic to humans and animals than aminoglycosides.
- the compound of the present invention is mixed with a pharmaceutically acceptable carrier and administered orally or parenterally as a solid preparation such as tablets, capsules, granules and powders; or as a liquid preparation such as syrups and injections. Can be.
- the pharmaceutically acceptable carrier various organic or inorganic carrier materials commonly used as a drug substance are used.
- excipients various organic or inorganic carrier materials commonly used as a drug substance are used.
- excipients various organic or inorganic carrier materials commonly used as a drug substance are used.
- solid preparations excipients, lubricants, binders are used.
- Disintegrant In the liquid preparation, a solvent, a solubilizing agent, a suspending agent, an isotonic agent, a buffer, a soothing agent and the like are appropriately compounded.
- pharmaceutical additives such as preservatives, antioxidants, coloring agents, sweeteners and the like can be used in accordance with ordinary methods.
- Preferred examples of the excipient include lactose, sucrose, D-mannitol, starch, crystalline cellulose, light gay anhydride and the like.
- Preferred examples of the lubricant include magnesium stearate, calcium stearate, talc, colloid silica and the like.
- Preferred examples of the binder include crystalline cellulose, sucrose, D-mannitol, dextrin, hydroxypropylcellulose, hydroxyquinpropylmethylcellulose, polyvinylpyrrolidone, and the like.
- Preferable examples of the disintegrant include starch, carboxymethylcellulose, carboxymethylcellulose calcium, croscarmellose sodium, carboxymethyl starch sodium and the like.
- Preferred examples of the solvent include water for injection, alcohol, propylene glycol, macrogol, sesame oil, corn oil and the like.
- solubilizer examples include polyethylene glycol, propylene glycol, D-mannitol, benzyl benzoate, ethanol, trisaminomethane, cholesterol, triethanolamine, sodium carbonate, and sodium citrate. And the like.
- suspending agent examples include surfactants such as stearyltriethanolamine, sodium lauryl sulfate, laurylaminopropionic acid, lecithin, benzalkonium chloride, benzethonium chloride, glycerin monostearate, etc .; polyvinyl alcohol, Examples include hydrophilic polymers such as polyvinylpyrrolidone, sodium carboxymethylcellulose, methylcellulose, hydroxymethylcellulose, hydroxyshethylcellulose, and hydroxylated pilcellulose.
- Preferred examples of the tonicity agent include sodium chloride, glycerin, D-mannitol and the like.
- Buffer Preferable examples include buffers such as phosphate, acetate, carbonate, and citrate.
- Preferred examples of the soothing agent include benzyl alcohol and the like.
- Preferable examples of the preservative include paraoxybenzoic acid esters, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid, sorbic acid and the like.
- Preferred examples of the antioxidant include sulphite, ascorbic acid and the like.
- other active ingredients eg, -lactam antibiotics
- the compound of the present invention can be used as a therapeutic agent for bacterial infections, for example, respiratory tract infections, urinary tract infections, suppurative diseases, biliary tract infections, intestinal infections, obstetrics and gynecology infections, otolaryngology It can be used for treatment and prevention of infectious diseases and surgical infections.
- the dosage, the patient's condition and body weight, the method of administration, and the like, for parenteral administration, 80 mg of about 0.5 as adult weighing 1 _ kg of active ingredient per, good Mashiku is from about 2 4 Omg It is appropriate to administer by intravenous or intramuscular injection in 1 to 3 times daily.
- the appropriate oral dose is about 1 to 10 Omg, preferably about 2.5 to 5 Oing, per 1 kg of adult body weight, divided into 1 to 3 times per day.
- THF tetrahydrofuran: DBU: 1,8-diazavinclo [5,4,0] pendene; DMF: dimethylformamide; DMS ⁇ : dimethyl sulfoxide; DIB AH: diisobutylaluminum hydride; TMS: trimethylsilyl; Me: methyl; Et: ethyl; iPr: isopropyl; 1 Bu: tert-butyl; Ph: phenyl; MsC1: methanesulfonyl chloride (Protecting group)
- Body ti (1) 2-0 864fflg (5 mmol) was dissolved in 1 Oml of formic acid, and after adding 417 mg (6 mniol) of hydroxylamine hydrochloride, the mixture was stirred at 110 ° C for 6 hours.
- the reaction solution was concentrated under reduced pressure.
- the residue was dissolved in water, neutralized with NaHCO 3, and the precipitated crystals were collected by filtration. Recrystallization from methanol afforded _ 394 mg (yield: 46.6%).
- reaction solution was concentrated under reduced pressure, the residue was dissolved in 150 ml of water, neutralized with 2N NaOH, and the precipitated insoluble crystals were collected by filtration, washed with water, and dried to obtain 6.78 g of H (yield: 89.9%). .
- H 2 NCN55 ImgCl 3.Immol was dissolved in 30 ml of DMF, and 439 mg (l 0.9 niniol) of NaH was added, followed by stirring at room temperature for 10 minutes. This solution was ice-cooled, added to the solution in (1), and stirred at 120 ° C for 1 hour and 30 minutes. 10.9 ml of 2N-HCl was added to the obtained solution, and the mixture was distilled off under reduced pressure. The residue is poured H 2 0, NaHC0 3 917mg of (l 0.9 mmol) was added, and filtered the insoluble matter, yellow crystals 57 3.31 g by washing with Echirue ether (yield: 93%) was obtained. mp 230-235 ° C.
- the precipitated solid was washed with water, dissolved in methanol 40 OinlZ ethyl acetate 30 Oml, added with toluene 200 ml, concentrated under reduced pressure, and the precipitated solid was collected by filtration.White powder 81 10.5 7 g (66.8% ). mp 211-214 ° C.
- IR (Nujol) level or 1 3272, 2718, 2240, 2148, 1670, 1596, 1523, 1374, 1323, 1206.1193.1015
- reaction solution was concentrated under reduced pressure, 128.7 ml of IN NaOH was added to the residue, and the precipitated crystals were collected by filtration, washed sequentially with H 2 O and ethyl ether, and dried to obtain 99 64 g of yellow crystals.
- one 30 ° to C after cooling was dissolved in concentrated HC 126 ml and H 2 0 51.5 ml, further added H 2 NNH 2 ⁇ H 2 09. Oml (l 85mmol), 40 minutes at 85 ° C Stirred.
- IR (CHC1 3 ) cur 1 2980, 1658, 1605. 1570, 14 40.1377, 1328, 1190
- IR (CHC1 3 ) vein- 1 2970, 1715, 1600, 1430, 13 75, 1290, 1265, 1240, 1220
- the intermediate I- ⁇ may be obtained as a salt in which pyridinum cation is neutralized with an inorganic anion such as I-, depending on the conditions of isolation and purification.
- the compound can be converted to compound I-1 'by deprotection.
- Example 3 (1) V-2.91 Og (l.2mniol) and 240 mg (0.9 mmol) as starting materials were reacted in the same manner as in Example 1 to obtain 1-0,79 g (yield: 85.4% ).
- IR (KB r) record cur 1 2250, 2156, 1784, 1715.
- ATDZ— stands for BocNH- ⁇ II
- 1111101) was dissolved in anhydrous 01 ⁇ 30 (7 ml), V- ⁇ 83 Omg (l.09mraol) was added at room temperature under N 2 gas stream, and the mixture was stirred for 1 hour. . Thereafter, the reaction solution was poured into 7% of 5% saline, and the precipitated solid was collected by filtration. It was dissolve in a mixture of Asetonitoriru 4 OmlZCHC S Oral, dried over MgSO 4, then concentrated under reduced pressure, the resulting residue is taken up in acetic acid Echiru 5 OML, and collecting a deposited precipitate by filtration, dried, yellow Powder I-1 7
- IR (KBr) level cnr 1 2970, 2148, 1784, 1711, 1635, 1548
- reaction solution was dropped into a mixture of IN HC11 Oml and 5% saline 1 Oml under ice-cooling, and ethyl ether (8 Oml) was added, and the precipitated solid was collected. It was wash with IN HC 1 and H 2 0, was subjected to column purification was dissolved in NaHCO 3. 7% acetonitrile / 0.05N NaHC03 3 The eluted part was adjusted to pH 2.9, concentrated under reduced pressure, and precipitated. The solid which had collected was collected by filtration. It H 2 0, isopropanol, washed with Echirueteru to give a pale yellow powder I once '' 266 mg of (49.4%).
- Boc-protected 70 150 mg (0.43 mmol) and V- 1 328 mg (0.43 ramol) from yellow-brown powder I-10'45 1 mg was obtained.
- IR (KBr) level cnr 1 2984, 2257.2157, 1775, 1671, 1623, 1564, 1348, 1 155
- IR (KBr) level cm- 1 2970, 2166, 1787, 1712, 1632, 1539, 1245, 1151, 855
- N, 0-bis (trimethylsilinole) acetamide 292 / zl (1.2 mniol) was added dropwise with stirring, and V- 1.195 g (l.26 dragonol) was further added.
- the mixture was stirred at room temperature for 85 minutes. Then, the reaction mixture was washed with 5% saturated saline
- yellow-brown powder I (485 mg, 99%) was obtained from _ (Z) 162 mg (0.642 mniol) and V- ⁇ 55 52 mg (0.706 mmol).
- the MIC minimal inhibitory concentration was determined by the agar dilution method. That is, 1.0 ml of a sequentially diluted aqueous solution of the test compound was poured into a petri dish, and then 9.0 ml of trypticase soy agar was poured and mixed. To the mixture agar plates, a suspension of test bacteria (approximately 10 6 CFU / ml) was smeared. After overnight incubation at 37 ° C, the MIC was the lowest concentration of the test compound that completely inhibited the growth of the test organism.
- Test bacteria Gram-positive: S. pyogenes C-203, S. agalactiae ATCC13813, S. neumoniae Type I, S. pneumoniae SR16675 (PC-R), S. mitis ATCC9811; Gram-negative: K. pneumoniae SRI, P mirabilis P -4, P. vulgaris CN-329 Results:
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cephalosporin Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/147,074 US6214818B1 (en) | 1996-04-04 | 1997-04-04 | Cephem compounds and pharmaceutical compositions containing the same |
DE69736775T DE69736775T2 (en) | 1996-04-04 | 1997-04-04 | CEPHEM COMPOUNDS AND MEDICAMENTS CONTAINING THESE COMPOUNDS |
CA002250002A CA2250002C (en) | 1996-04-04 | 1997-04-04 | Cephem compounds and drugs containing the compounds |
EP97914600A EP0893446B1 (en) | 1996-04-04 | 1997-04-04 | Cephem compounds and drugs containing the compounds |
AU21784/97A AU2178497A (en) | 1996-04-04 | 1997-04-04 | Cephem compounds and drugs containing the compounds |
JP53604897A JP4064462B2 (en) | 1996-04-04 | 1997-04-04 | Cephem compound and pharmaceutical containing the compound |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP8/82531 | 1996-04-04 | ||
JP8253196 | 1996-04-04 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/631,947 Division US6458950B1 (en) | 1996-04-04 | 2000-08-03 | Compounds and pharmaceutical compositions containing the same |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997037996A1 true WO1997037996A1 (en) | 1997-10-16 |
Family
ID=13777098
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1997/001161 WO1997037996A1 (en) | 1996-04-04 | 1997-04-04 | Cephem compounds and drugs containing the compounds |
Country Status (11)
Country | Link |
---|---|
US (2) | US6214818B1 (en) |
EP (3) | EP0893446B1 (en) |
JP (1) | JP4064462B2 (en) |
KR (1) | KR20000005238A (en) |
CN (2) | CN1088711C (en) |
AT (1) | ATE341554T1 (en) |
AU (1) | AU2178497A (en) |
CA (1) | CA2250002C (en) |
DE (1) | DE69736775T2 (en) |
ES (1) | ES2273364T3 (en) |
WO (1) | WO1997037996A1 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998022469A1 (en) * | 1996-11-22 | 1998-05-28 | Meiji Seika Kaisha, Ltd. | Cephem intermediates and process for producing the same |
WO2006104141A1 (en) * | 2005-03-29 | 2006-10-05 | Shionogi & Co., Ltd. | 3-propenylcephem derivative |
JP2014521653A (en) * | 2011-07-29 | 2014-08-28 | カリオファーム セラピューティクス,インコーポレイテッド | Nuclear transport regulators and uses thereof |
US9714226B2 (en) | 2011-07-29 | 2017-07-25 | Karyopharm Therapeutics Inc. | Hydrazide containing nuclear transport modulators and uses thereof |
US9738624B2 (en) | 2013-06-21 | 2017-08-22 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
US9861614B2 (en) | 2012-05-09 | 2018-01-09 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
US10202366B2 (en) | 2013-03-15 | 2019-02-12 | Karyopharm Therapeutics Inc. | Methods of promoting wound healing using CRM1 inhibitors |
US10519139B2 (en) | 2014-08-15 | 2019-12-31 | Karyopharm Therapeutics Inc. | Polymorphs of Selinexor |
US10526295B2 (en) | 2015-12-31 | 2020-01-07 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
US10709706B2 (en) | 2015-12-31 | 2020-07-14 | Karopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
US11602530B2 (en) | 2016-11-28 | 2023-03-14 | Biogen Ma Inc. | CRM1 inhibitors for treating epilepsy |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1394159A1 (en) * | 2002-08-13 | 2004-03-03 | Warner-Lambert Company LLC | New thiophene derivatives, process for their preparation and pharmaceutical compositions containing them |
US20080021217A1 (en) * | 2006-07-20 | 2008-01-24 | Allen Borchardt | Heterocyclic inhibitors of rho kinase |
CN101153028B (en) * | 2006-09-30 | 2010-12-15 | 山东轩竹医药科技有限公司 | Compounds with antimicrobial antiviral activity |
LT3616695T (en) | 2011-09-09 | 2024-11-25 | Merck Sharp & Dohme Llc | Ceftolozane/tazobactam for treating intrapulmonary infections |
US8809314B1 (en) | 2012-09-07 | 2014-08-19 | Cubist Pharmacueticals, Inc. | Cephalosporin compound |
US8476425B1 (en) | 2012-09-27 | 2013-07-02 | Cubist Pharmaceuticals, Inc. | Tazobactam arginine compositions |
US20140274992A1 (en) | 2013-03-15 | 2014-09-18 | Cubist Pharmaceuticals, Inc. | Ceftolozane pharmaceutical compositions |
US9872906B2 (en) | 2013-03-15 | 2018-01-23 | Merck Sharp & Dohme Corp. | Ceftolozane antibiotic compositions |
US20140274990A1 (en) | 2013-03-15 | 2014-09-18 | Cubist Pharmaceuticals, Inc. | Ceftolozane pharmaceutical compositions |
WO2015035376A2 (en) | 2013-09-09 | 2015-03-12 | Calixa Therapeutics, Inc. | Treating infections with ceftolozane/tazobactam in subjects having impaired renal function |
US20150094293A1 (en) | 2013-09-27 | 2015-04-02 | Calixa Therapeutics, Inc. | Solid forms of ceftolozane |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57192394A (en) * | 1981-05-12 | 1982-11-26 | Hoechst Ag | Cephalosporin derivatives and manufacture |
JPS58162592A (en) * | 1982-03-04 | 1983-09-27 | ヘキスト アクチェンゲゼルシャフト | Cephalosporin derivative and manufacture |
JPS6064988A (en) * | 1983-09-21 | 1985-04-13 | Sankyo Co Ltd | Cephalosporin derivative |
JPS60237090A (en) * | 1984-02-21 | 1985-11-25 | Takeda Chem Ind Ltd | Cephem compound |
JPS6253993A (en) * | 1985-08-10 | 1987-03-09 | ビ−チヤム・グル−プ・ピ−エルシ− | Novel compound, its production and pharmaceutical composition containing said compound |
JPS62158291A (en) * | 1986-01-07 | 1987-07-14 | Sagami Chem Res Center | Cephalosporin derivative |
JPH0459730A (en) * | 1990-06-26 | 1992-02-26 | Dai Ichi Seiyaku Co Ltd | Cephem-based antibiotic-containing lyophilized preparation |
JPH05271239A (en) * | 1992-01-27 | 1993-10-19 | Katayama Seiyakushiyo:Kk | Cephem compound and antimicrobial agent |
JPH0741485A (en) * | 1993-07-30 | 1995-02-10 | Katayama Seiyakushiyo:Kk | Cephem derivative and antimicrobial agent containing the same |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5271239A (en) * | 1975-12-10 | 1977-06-14 | Matsushita Electric Ind Co Ltd | Electron beam sensitive material |
JPS62158290A (en) * | 1985-12-28 | 1987-07-14 | Banyu Pharmaceut Co Ltd | New cephalosporin derivatives |
US5202321A (en) * | 1991-06-13 | 1993-04-13 | Merck Frosst Canada, Inc. | Thiopyrano[2,3,4-c,d]indoles as inhibitors of leukotriene biosynthesis |
JPH05217239A (en) * | 1991-10-31 | 1993-08-27 | Sony Corp | Recording and reproducing device for magneto-optical disk |
-
1997
- 1997-04-04 WO PCT/JP1997/001161 patent/WO1997037996A1/en active IP Right Grant
- 1997-04-04 DE DE69736775T patent/DE69736775T2/en not_active Expired - Fee Related
- 1997-04-04 EP EP97914600A patent/EP0893446B1/en not_active Expired - Lifetime
- 1997-04-04 KR KR1019980707925A patent/KR20000005238A/en not_active Ceased
- 1997-04-04 CN CN97193623A patent/CN1088711C/en not_active Expired - Fee Related
- 1997-04-04 EP EP05006670A patent/EP1544197A1/en not_active Withdrawn
- 1997-04-04 US US09/147,074 patent/US6214818B1/en not_active Expired - Fee Related
- 1997-04-04 ES ES97914600T patent/ES2273364T3/en not_active Expired - Lifetime
- 1997-04-04 EP EP06005931A patent/EP1671966A1/en not_active Withdrawn
- 1997-04-04 CA CA002250002A patent/CA2250002C/en not_active Expired - Fee Related
- 1997-04-04 AT AT97914600T patent/ATE341554T1/en not_active IP Right Cessation
- 1997-04-04 AU AU21784/97A patent/AU2178497A/en not_active Abandoned
- 1997-04-04 JP JP53604897A patent/JP4064462B2/en not_active Expired - Fee Related
-
2000
- 2000-08-03 US US09/631,947 patent/US6458950B1/en not_active Expired - Fee Related
- 2000-08-15 CN CN00124231A patent/CN1129596C/en not_active Expired - Fee Related
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57192394A (en) * | 1981-05-12 | 1982-11-26 | Hoechst Ag | Cephalosporin derivatives and manufacture |
JPS58162592A (en) * | 1982-03-04 | 1983-09-27 | ヘキスト アクチェンゲゼルシャフト | Cephalosporin derivative and manufacture |
JPS6064988A (en) * | 1983-09-21 | 1985-04-13 | Sankyo Co Ltd | Cephalosporin derivative |
JPS60237090A (en) * | 1984-02-21 | 1985-11-25 | Takeda Chem Ind Ltd | Cephem compound |
JPS6253993A (en) * | 1985-08-10 | 1987-03-09 | ビ−チヤム・グル−プ・ピ−エルシ− | Novel compound, its production and pharmaceutical composition containing said compound |
JPS62158291A (en) * | 1986-01-07 | 1987-07-14 | Sagami Chem Res Center | Cephalosporin derivative |
JPH0459730A (en) * | 1990-06-26 | 1992-02-26 | Dai Ichi Seiyaku Co Ltd | Cephem-based antibiotic-containing lyophilized preparation |
JPH05271239A (en) * | 1992-01-27 | 1993-10-19 | Katayama Seiyakushiyo:Kk | Cephem compound and antimicrobial agent |
JPH0741485A (en) * | 1993-07-30 | 1995-02-10 | Katayama Seiyakushiyo:Kk | Cephem derivative and antimicrobial agent containing the same |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998022469A1 (en) * | 1996-11-22 | 1998-05-28 | Meiji Seika Kaisha, Ltd. | Cephem intermediates and process for producing the same |
WO2006104141A1 (en) * | 2005-03-29 | 2006-10-05 | Shionogi & Co., Ltd. | 3-propenylcephem derivative |
US10544108B2 (en) | 2011-07-29 | 2020-01-28 | Karyopharm Therapeutics Inc. | Hydrazide containing nuclear transport modulators and uses thereof |
JP2014521653A (en) * | 2011-07-29 | 2014-08-28 | カリオファーム セラピューティクス,インコーポレイテッド | Nuclear transport regulators and uses thereof |
US9714226B2 (en) | 2011-07-29 | 2017-07-25 | Karyopharm Therapeutics Inc. | Hydrazide containing nuclear transport modulators and uses thereof |
US12291508B2 (en) | 2011-07-29 | 2025-05-06 | Karyopharm Therapeutics Inc. | Hydrazide containing nuclear transport modulators and uses thereof |
US11787771B2 (en) | 2011-07-29 | 2023-10-17 | Karyopharm Therapeutics Inc. | Hydrazide containing nuclear transport modulators and uses thereof |
US11034660B2 (en) | 2011-07-29 | 2021-06-15 | Karyopharm Therapeutics Inc. | Hydrazide containing nuclear transport modulators and uses thereof |
US10173987B2 (en) | 2011-07-29 | 2019-01-08 | Karyopharm Therapeutics Inc. | Hydrazide containing nuclear transport modulators and uses thereof |
US10617677B2 (en) | 2012-05-09 | 2020-04-14 | Biogen Ma Inc. | Nuclear transport modulators and uses thereof |
US11318120B2 (en) | 2012-05-09 | 2022-05-03 | Biogen Ma Inc. | Nuclear transport modulators and uses thereof |
US10335393B2 (en) | 2012-05-09 | 2019-07-02 | Biogen Ma Inc. | Nuclear transport modulators and uses thereof |
US9861614B2 (en) | 2012-05-09 | 2018-01-09 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
US10925859B2 (en) | 2012-05-09 | 2021-02-23 | Biogen Ma Inc. | Nuclear transport modulators and uses thereof |
US10058535B2 (en) | 2012-05-09 | 2018-08-28 | Biogen Ma Inc. | Nuclear transport modulators and uses thereof |
US10202366B2 (en) | 2013-03-15 | 2019-02-12 | Karyopharm Therapeutics Inc. | Methods of promoting wound healing using CRM1 inhibitors |
US9738624B2 (en) | 2013-06-21 | 2017-08-22 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
US11945794B2 (en) | 2013-06-21 | 2024-04-02 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
US10407405B2 (en) | 2013-06-21 | 2019-09-10 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
US11124493B2 (en) | 2013-06-21 | 2021-09-21 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
US11078190B2 (en) | 2014-08-15 | 2021-08-03 | Karyopharm Therapeutics Inc. | Polymorphs of selinexor |
US11746102B2 (en) | 2014-08-15 | 2023-09-05 | Karyopharm Therapeutics Inc. | Polymorphs of selinexor |
US11753401B2 (en) | 2014-08-15 | 2023-09-12 | Karyopharm Therapeutics Inc. | Polymorphs of Selinexor |
US11807629B2 (en) | 2014-08-15 | 2023-11-07 | Karyopharm Therapeutics Inc. | Polymorphs of Selinexor |
US10519139B2 (en) | 2014-08-15 | 2019-12-31 | Karyopharm Therapeutics Inc. | Polymorphs of Selinexor |
US10709706B2 (en) | 2015-12-31 | 2020-07-14 | Karopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
US10526295B2 (en) | 2015-12-31 | 2020-01-07 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
US11602530B2 (en) | 2016-11-28 | 2023-03-14 | Biogen Ma Inc. | CRM1 inhibitors for treating epilepsy |
Also Published As
Publication number | Publication date |
---|---|
KR20000005238A (en) | 2000-01-25 |
DE69736775D1 (en) | 2006-11-16 |
CA2250002C (en) | 2008-03-25 |
CN1215403A (en) | 1999-04-28 |
AU2178497A (en) | 1997-10-29 |
JP4064462B2 (en) | 2008-03-19 |
EP0893446A1 (en) | 1999-01-27 |
CN1290702A (en) | 2001-04-11 |
CN1088711C (en) | 2002-08-07 |
US6458950B1 (en) | 2002-10-01 |
EP1544197A1 (en) | 2005-06-22 |
CA2250002A1 (en) | 1997-10-16 |
ES2273364T3 (en) | 2007-05-01 |
US6214818B1 (en) | 2001-04-10 |
EP0893446B1 (en) | 2006-10-04 |
EP0893446A4 (en) | 1999-01-27 |
DE69736775T2 (en) | 2007-08-23 |
EP1671966A1 (en) | 2006-06-21 |
ATE341554T1 (en) | 2006-10-15 |
CN1129596C (en) | 2003-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1997037996A1 (en) | Cephem compounds and drugs containing the compounds | |
CN103228652B (en) | monocyclic lactams | |
JP5852562B2 (en) | Novel cephem derivatives | |
WO2000032606A1 (en) | IMIDAZO[4,5-b]PYRIDINIUMMETHYL-CONTAINING CEPHEM COMPOUNDS HAVING BROAD ANTIBACTERIAL SPECTRUM | |
JPH0853453A (en) | 2- [1- (1,3-thiazolin-2-yl) azetidin-3-yl] thio-carbapenem compound | |
MX2007014507A (en) | Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity. | |
WO2006104141A1 (en) | 3-propenylcephem derivative | |
MXPA04008320A (en) | Broad-spectrum cephem compounds. | |
CN102317286A (en) | 2-(piperidin-1-yl)-4-heterocyclyl-thiazole-5-carboxylic acid derivatives against bacterial infections | |
JP2008531671A (en) | Compound | |
JPH09512549A (en) | Novel quinolone 5- (N-hetero-substituted amino) antimicrobial agent | |
RU2126000C1 (en) | Derivatives of 5-hydrazinoquinolone, composition for treatment and prophylaxis of infection disease, method of treatment and prophylaxis | |
AU2016367284B2 (en) | Cephem compounds, their production and use | |
WO1992000981A1 (en) | Novel 3-substituted cephem compounds and processes for preparation thereof | |
EP0153709B1 (en) | Novel cephalosporin derivatives | |
CN109195968A (en) | Condensed five rings imdazole derivatives as TNF active regulator | |
WO2009030106A1 (en) | 7-(4-oximino-3-amino-1-piperidyl)quinolinecarboxylic acid derivatives and their preparation methods | |
WO2022161479A1 (en) | Toxin molecule suitable for antibody-drug conjugate | |
WO2009106967A1 (en) | Novel 7-substituted derivatives of 3-carboxy-oxadiazino-quinolones, preparation thereof and use thereof as anti-bacterial agents | |
CN109415365A (en) | Carbapenem compounds | |
JP3238209B2 (en) | Thiomethylthiocarbacephalosporin derivative | |
CA2008059A1 (en) | Cephalosporin derivatives and processes for their preparation | |
WO2024077650A1 (en) | Salt form of compound having substituted sulfonylurea ring and crystal form thereof | |
WO2024188214A1 (en) | Tricyclic compound, and preparation and application thereof | |
JPH0812676A (en) | 2-((pyridyl-substituted)thio)-carbapenem derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 97193623.4 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2250002 Country of ref document: CA Ref document number: 2250002 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997914600 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09147074 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019980707925 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 1997914600 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1019980707925 Country of ref document: KR |
|
WWR | Wipo information: refused in national office |
Ref document number: 1019980707925 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1997914600 Country of ref document: EP |